首页 > 市场调查报告书 > 製药

妇科治疗

市场调查报告书

商品编码

1274335

子宫内膜异位症治疗全球市场研究报告——2023-2030 年行业分析、规模、份额、增长、趋势和预测

Global Endometriosis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年05月01日 | 出版商:

Value Market Research | 英文 210 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

在 2023-2030 研究期间，全球对子宫内膜异位症治疗市场的需求将以 25.62% 的复合年增长率增长，从 2022 年的 54.4 亿美元增长到 2030 年的近 337.3 亿美元，预计将达到

子宫内膜异位症是一种痛苦的妇科疾病，类似于子宫内膜的组织开始在腹部和骨盆的其他部位生长。子宫内膜异位症可发生在输卵管、阴道、肠、直肠、隔膜、膀胱和输尿管，以及子宫外和子宫后。症状包括月经期间剧烈疼痛、痉挛、性交疼痛、月经期间大量出血、排便疼痛和月经期间腹痛。给予止痛药和激素治疗以缓解子宫内膜异位症的症状。治疗子宫内膜异位症的手术选择包括腹腔镜检查和子宫切除术。

市场动态：

由于病例数的增加和对子宫内膜异位症治疗需求的增长，对子宫内膜异位症治疗市场的需求正在扩大。一些国家已经实施了政府举措和宣传计划，以提高公众对这种疾病的认识，导致对该市场的需求激增。此外，与发现更好的治疗方法相关的越来越多的研发活动正在推动对该市场的需求。针对昂贵药物的患者援助计划正在增加对该市场的需求。此外，增加对医疗保健行业的投资以提供更好的治疗设施正在推动该市场的增长。相反，子宫内膜异位症的非侵入性诊断测试不可用可能会阻碍子宫内膜异位症治疗市场的增长。

研究报告描述了波特的五力模型、市场吸引力分析和价值链分析。这些工具可帮助您清楚地了解您的行业结构并评估您在全球范围内的竞争吸引力。此外，这些工具还对全球子宫内膜异位症治疗市场的每个细分市场进行了全面评估。子宫内膜异位症药物行业的发展和趋势为这项研究提供了一个整体的方法。

市场细分：

子宫内膜异位症治疗市场报告的这一部分提供了有关国家和地区层面细分市场的详细数据，从而帮助战略制定者确定目标受众和他们各自产品或服务的即将到来的机会。以支持

按治疗类型

止痛药
激素疗法

按药物类别

非甾体抗炎药
口服避孕药
促性腺激素释放激素
其他

按给药途径

口语
注射
其他

按销售渠道

医院药房
零售店
其他

按地区分析：

本节介绍了区域前景，重点关注北美、欧洲、亚太地区、拉丁美洲、中东和非洲子宫内膜异位症治疗市场当前和未来的需求。此外，我们还关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的综合概况和全球竞争格局的详细视图。子宫内膜异位症治疗市场的主要参与者是拜耳公司、辉瑞公司、艾伯维公司、阿斯利康公司、ObsEva SA、Teva Pharmaceutical Industries、Zydus Healthcare Limited、Eli Lilly and Company、Astellas Pharma Inc。本节包括主要併购，它由全面的竞争格局的观点，包括各种战略发展，如未来能力、合作伙伴关係、财务概览、合作、新产品开发和新产品发布。

如果您有定制要求，请联繫我们。我们的研究团队可以根据您的需要提供定制报告。

内容

第一章前言

本报告的内容
- 目的
- 目标受众
- 独特的销售建议 (USP) 和提供的服务
调查范围
调查方法
- 市场调研过程
- 市场研究方法

第 2 章执行摘要

市场亮点
全球市场概况

第三章子宫内膜异位症治疗-行业分析

简介 - 市场动态
市场驱动因素
市场製约因素
市场机会
行业趋势
波特的五力分析
市场吸引力分析
- 按治疗类型进行的市场吸引力分析
- 按药物类别进行的市场吸引力分析
- 按给药途径进行的市场吸引力分析
- 按分销渠道进行的市场吸引力分析
- 市场吸引力分析：按地区

第四章价值链分析

价值链分析
原材料分析
- 原材料清单
- 原材料製造商列表
- 主要原材料价格走势
潜在买家名单
营销渠道
- 直接营销
- 间接营销
- 营销渠道趋势

第 5 章 COVID-19 爆发的影响分析

第 6 章按治疗类型分列的全球子宫内膜异位症治疗市场分析

治疗类型概述
实际数据和预测数据
按治疗类型分析
止痛药
激素疗法

第 7 章子宫内膜异位症治疗的全球市场分析：按药物分类

按药物类别汇总
实际数据和预测数据
按药物类别分析
非甾体抗炎药
口服避孕药
促性腺激素释放激素
其他

第 8 章子宫内膜异位症药物给药途径的全球市场分析

按给药途径汇总
实际数据和预测数据
给药途径分析
口服剂
注射
其他

第 9 章子宫内膜异位症药物分销渠道的全球市场分析

按分销渠道概述
实际数据和预测数据
按分销渠道分析
医院药房
零售药房
其他

第 10 章子宫内膜异位症药物的全球市场分析：按地区

区域展望
简介
北美销售分析
- 概览、历史和预测销售分析
- 北美各部门的销售分析
- 北美销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史和预测销售分析
- 按细分市场进行的欧洲销售分析
- 按国家/地区划分的欧洲销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 意大利销售分析
- 俄罗斯销售分析
- 其他欧洲销售分析
亚太地区销售分析
- 概览、历史和未来销售分析
- 亚太地区各部门的销售分析
- 亚太国家/地区销售分析
- 在中国的销售分析
- 印度销售分析
- 日本的销售分析
- 韩国销售分析
- 澳大利亚销售分析
- 其他亚太地区销售分析
拉丁美洲销售分析
- 概览、历史和未来销售分析
- 拉丁美洲各部门的销售分析
- 拉丁美洲国家/地区的销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利的销售分析
- 其他拉丁美洲销售分析
中东和非洲销售分析
- 概览、历史和未来销售分析
- 中东/非洲地区的销售分析
- 中东和非洲国家/地区的销售分析
- 沙特阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 其他中东和非洲销售分析

第11章子宫内膜异位症药物企业竞争状况

子宫内膜异位症药物市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第12章公司简介

顶级公司的市场份额分析
市场集中度
拜耳公司
- 公司简介
- 企业收入
- 产品介绍
- 近期发展状况
辉瑞公司
- 公司简介
- 企业收入
- 产品信息
- 近期发展状况
艾伯维公司
- 公司简介
- 企业收入
- 产品信息
- 近期发展状况
阿斯利康
- 公司简介
- 企业收入
- 产品信息
- 近期发展状况
Obs Eva SA
- 公司简介
- 企业收入
- 产品信息
- 近期发展状况
Teva 製药工业
- 公司简介
- 企业收入
- 产品信息
- 近期发展状况
Zydus 医疗保健有限公司
- 公司简介
- 企业收入
- 产品信息
- 近期发展状况
礼来公司
- 公司简介
- 企业收入
- 产品信息
- 近期发展状况
安斯泰来製药公司
- 公司简介
- 企业收入
- 产品信息
- 近期趋势

注意：公司简介中的财务细节和近期发展基于可用信息，可能不包括私营公司。

简介目录图表

Product Code: VMR112110345

The global demand for Endometriosis Treatment Market is presumed to reach the market size of nearly USD 33.73 BN by 2030 from USD 5.44 BN in 2022 with a CAGR of 25.62% under the study period 2023 - 2030.

Endometriosis is a painful gynaecological disorder in which endometrial-like tissues start growing in other parts of the abdomen and pelvic areas. Some places where endometriosis can develop are the fallopian tubes, vagina, intestine, rectum, diaphragm, bladder and ureter, outside and back of the uterus etc. Its symptoms may include heavy pain during menstruation, cramps, pain during sex, heavy bleeding during periods, painful bowel movements, abdominal pain during periods and others. Pain medications and hormone therapy are used to reduce the symptoms of endometriosis. The surgical options for the treatment of endometriosis are laparoscopy as well as hysterectomy.

Market Dynamics:

The demand for the endometriosis treatment market is scaling up due to the rising number of cases and the growing need for treatment of endometriosis. Government initiative and awareness programs across several countries to create awareness regarding this disease among people is surging the demand for this market. Moreover, the rise in research and development activities associated with discovering better treatment options propels the demand for this market. Patient assistance programs for expensive drugs are augmenting the demand for this market. Furthermore, growing investment in healthcare sectors to provide better treatment facilities is boosting the growth of this market. Conversely, the unavailability of non-invasive diagnostic tests for endometriosis may obstruct the growth of the endometriosis treatment market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of endometriosis treatment. The growth and trends of endometriosis treatment industry provide a holistic approach to this study.

Market Segmentation:

This section of the endometriosis treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Type

Pain Medication
Hormone Therapy

By Drug Class

NSAIDs
Oral Contraceptive
Gonadotropin Releasing Hormone
Others

By Route Of Administration

Oral
Injectable
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Others

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Endometriosis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the endometriosis treatment market include Bayer AG, Pfizer Inc., AbbVie Inc, AstraZeneca, ObsEva SA, Teva Pharmaceutical Industries, Zydus Healthcare Limited, Eli Lilly and Company, Astellas Pharma Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ENDOMETRIOSIS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment Type
- 3.7.2 Market Attractiveness Analysis By Drug Class
- 3.7.3 Market Attractiveness Analysis By Route Of Administration
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

6.1 Overview by Treatment Type
6.2 Historical and Forecast Data
6.3 Analysis by Treatment Type
6.4 Pain Medication Historic and Forecast Sales by Regions
6.5 Hormone Therapy Historic and Forecast Sales by Regions

7 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY DRUG CLASS

7.1 Overview by Drug Class
7.2 Historical and Forecast Data
7.3 Analysis by Drug Class
7.4 NSAIDs Historic and Forecast Sales by Regions
7.5 Oral Contraceptive Historic and Forecast Sales by Regions
7.6 Gonadotropin Releasing Hormone Historic and Forecast Sales by Regions
7.7 Others Historic and Forecast Sales by Regions

8 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

8.1 Overview by Route Of Administration
8.2 Historical and Forecast Data
8.3 Analysis by Route Of Administration
8.4 Oral Historic and Forecast Sales by Regions
8.5 Injectable Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

9.1 Overview by Distribution Channel
9.2 Historical and Forecast Data
9.3 Analysis by Distribution Channel
9.4 Hospital Pharmacy Historic and Forecast Sales by Regions
9.5 Retail Pharmacy Historic and Forecast Sales by Regions
9.6 Others Historic and Forecast Sales by Regions

10 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE ENDOMETRIOSIS TREATMENT COMPANIES

11.1. Endometriosis Treatment Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF ENDOMETRIOSIS TREATMENT INDUSTRY

12.1. Top Company Share Analysis
12.2. Market Concentration Rate
12.3. Bayer AG
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Pfizer Inc.
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. AbbVie Inc
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. AstraZeneca
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. ObsEva SA
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. Teva Pharmaceutical Industries
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Zydus Healthcare Limited
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Eli Lilly and Company
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments
12.11. Astellas Pharma Inc.
- 12.11.1. Company Overview
- 12.11.2. Company Revenue
- 12.11.3. Products
- 12.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

简介目录图表